Arovella Therapeutics doses first patient in SAPPHIRE Phase 1 trial
Key points
- Arovella Therapeutics administered its cell therapy candidate to the first trial patient.
- Shares traded lower down to $0.048 following the clinical milestone announcement.
- The trial aims to evaluate safety, tolerability, and early clinical performance of off-the-shelf cells.
Arovella Therapeutics (ASX:ALA) has dosed its first patient in the SAPPHIRE phase 1 trial of cell therapy ALA-101.
The open-label clinical study marks the transition of the treatment candidate into first-in-human testing.
"ALA-101 has been designed to overcome key limitations of conventional CAR-T therapies by using healthy donor-derived iNKT cells that can be manufactured in advance and supplied when needed," said Lead Investigator Dr Sam Fiorenza.
The company stated that its off-the-shelf cell therapy uses healthy donor-derived cells manufactured in advance to reduce costs and treatment delays.
Following the announcement, the Arovella Therapeutics share price was down at $0.048.
The company recently strengthened its balance sheet after receiving a $4 million R&D tax rebate.
The trial will continue evaluating safety and preliminary efficacy across patients diagnosed with blood cancers.
Frequently asked questions
More from Australia
Dementia causes over 10% of Australian deaths
Immuron posts $2.2M quarterly sales revenue
Star Entertainment swings to Q1 profit with $12M EBITDA
Credit Corp seeks deals following failed Humm bid
Serko signals upward revenue revision to top guidance
Airtrunk secures $4.25B green loan for Sydney expansion
